GSK has announced encouraging results from its phase III clinical trials, ANCHOR-1 and ANCHOR-2, for depemokimab in treating chronic...

January 08, 2024 AbbVie aims to bring another HS therapy after Humira, announced positive Phase 2 trial of lutikizumab Positive outcomes...

AbbVie aims to advance its immunology pipeline by initiating a global Phase 3 trial of Rinvoq (upadacitinib) for Hidradenitis Suppurativa...

Eli Lilly announced the positive results of Phase 3 clinical trial of its drug, lebrikizumab, in treating atopic dermatitis. There was a...

AbbVie announced it would move Rinvoq (upadacitinib) into Phase 3 clinical trials to treat systemic lupus erythematosus (SLE). Rinvoq is...

EMA takes measures to reduce the risk of severe side effects with JAK inhibitors. The Committee for Medicinal Products for Human Use...

AbbVie published Phase 3 clinical trials of Skyrizi in Crohn's Disease. AbbVie announced that The Lancet had published the induction and...

AbbVie's immunology portfolio in Europe is strengthened with Skyrizi approval for psoriatic arthritis Approval is based on the trial...